Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor delta (NFKBID)
- Target
- NFKBID
- Molecular classification
- Transcription regulator (NF-κB inhibitor), Nuclear IκB protein
01
Overview
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor delta (NFKBID) is a nuclear protein of 327 amino acids belonging to the atypical nuclear inhibitors of NF-κB. It regulates NF-κB transcription factor activity, impacting immune responses, germinal center formation, and the development and function of B cells, plasma cells, and certain T cell populations. NFKBID functions as both inducer and inhibitor of NF-κB-dependent gene expression and is required for immunosuppressive regulatory T cell generation. Its deficiency or dysfunction has been linked to immune dysregulation and deficiency syndromes.
- Other names
- IκBNSIkBNSIκB-deltaIkappaBdeltaTA-NFKBHNFKB inhibitor deltaT-cell activation NFKB-like proteinnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor delta
02
Mechanism of action
Drugs affecting downstream NF-κB signaling may modulate NFKBID activity indirectly (activation or inhibition of NF-κB cascade)
03
Biological functions
Regulation of NF-κB signalingPromotion of germinal center reactionsImmune system homeostasisRegulation of B cell and plasma cell function/developmentRegulation of T helper 17 cell differentiationRegulation of cytokine expression (e.g., IL-2, IL-6)Inflammatory response
04
Disease associations
Immune deficiency (e.g., ectodermal dysplasia and immune deficiency)InflammationImmunological disordersPotential involvement in infection (via NF-κB pathway)
05
Safety considerations
Potential risks involve immunosuppression or unwanted immune activation due to disruption of NF-κB regulation; no specific issues reported for NFKBID
06
Interacting drugs
None directly reported for NFKBID; many known drugs target the NF-κB pathway but not specifically NFKBID
07
Biomarkers
None reported specifically for NFKBID; NF-κB activity in general is monitored using cytokine levels, but not NFKBID protein directly
Beyond the preview
Go deeper on Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor delta (NFKBID).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor delta (NFKBID).